Towa Pharmaceutical Co., Ltd.
4553.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥65,327 | ¥65,149 | ¥65,857 | ¥70,333 |
| % Growth | 0.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | ¥41,796 | ¥41,474 | ¥41,872 | ¥44,503 |
| Gross Profit | ¥23,531 | ¥23,675 | ¥23,985 | ¥25,830 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | ¥0 | ¥0 | ¥3,512 | ¥5,292 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥18,294 | ¥18,468 | ¥19,354 | ¥12,440 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥1 | -¥3,512 | ¥0 |
| Operating Expenses | ¥18,294 | ¥18,469 | ¥19,354 | ¥17,732 |
| Operating Income | ¥5,237 | ¥5,206 | ¥4,631 | ¥8,098 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | ¥2,758 | -¥1,246 | -¥132 | ¥3,433 |
| Pre-Tax Income | ¥7,995 | ¥3,960 | ¥4,499 | ¥11,531 |
| Tax Expense | ¥2,294 | ¥1,447 | ¥136 | ¥3,463 |
| Net Income | ¥5,701 | ¥2,513 | ¥4,362 | ¥8,069 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 115.81 | 51.05 | 88.61 | 163.92 |
| % Growth | 126.9% | -42.4% | -45.9% | – |
| EPS Diluted | 115.81 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 49 | 49 | 49 | 49 |
| Weighted Avg Shares Out Dil | 49 | 49 | 49 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥91 | ¥61 | ¥53 | ¥50 |
| Interest Expense | ¥609 | ¥540 | ¥465 | ¥386 |
| Depreciation & Amortization | ¥5,657 | ¥5,249 | ¥5,337 | ¥5,162 |
| EBITDA | ¥14,259 | ¥10,456 | ¥9,320 | ¥17,080 |
| % Margin | 21.8% | 16% | 14.2% | 24.3% |